India Rejects Extending Drug Patents In EU, UK Trade Talks

New Delhi : India has communicated its unwillingness to dilute its stance on data, intellectual property and government procurement to the European Union and the United Kingdom as part of ongoing trade agreement talks with them, officials said.

India is firm on its red lines on cross-border data flows as there is no ecommerce policy at present, while any commitments on data exclusivity and patent extensions would impact the manufacturing and distribution of generic medicines, they said.

On government procurement, India plans to stick to its stance to continue to reserve 25% for medium and small enterprises, officials said.

“The digital space and intellectual property rights are evolving areas. The red lines like data are to be kept away,” one of them told ET.

The IPR red line is of data exclusivity, which the EU has been seeking for a long. It is a provision that would hamper production of cheap generic medicines in the country, officials said.

The UK and the EU have sought amendment in India’s Patents Act to allow ‘evergreening’ of patents, especially in the pharmaceuticals sector. Section 3(d) of the Act prohibits the grant of ‘evergreening’ patents, which are additional patents for a drug with no therapeutic benefit and serve only to increase the term of patent monopoly.

“Patent monopolising is a red line for us and that’s clearly conveyed because  we want generics while the EU is strong in patented drugs,” said the official quoted above.

In government procurement, India has stated that it can’t compromise on the comforts given to small and medium enterprises.

Experts said India needs to be cautious about any commitments in services trade leading to cross-border data flows.

“Even if the UK shows flexibility on the digital front, India needs to be careful and not cede grounds in the services chapter,” a trade expert said.

Similarly, any commitments on digital trade will mark a permanent shift in India’s trade policy stance on ecommerce at the World Trade Organisation (WTO) where it is opposed to any binding commitments besides having implications for India’s security.

India has so far refrained from making any international commitments on digital trade in order to protect its policy space to design national digital sector policies in the future including on digital industrialisation.

  • Related Posts

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Meerut: A four-year-old boy’s condition allegedly worsened after he was administered an anti-rabies injection at Sambhal district hospital following a snakebite. A pharmacist at the hospital has been removed from…

    Lupin gets tentative US FDA nod for apixaban oral suspension for patients who cannot swallow tablets

    Once final approval comes through, the liquid anticoagulant will be made at Lupin’s plant in Somerset, New Jersey, the company said. Mumbai: Lupin has received tentative approval from the US…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore